Literature DB >> 4352464

Evidence for complement activation via the alternate pathway in skin diseases, I. Herpes gestationis, systemic lupus erythematosus, and bullous pemphigoid.

T T Provost, T B Tomasi.   

Abstract

A patient with herpes gestationis, 6 of 6 patients with bullous pemphigoid, and 5 of 25 patients with systemic lupus erythematosus were found to have properdin deposited along the skin basement membrane.The patient with herpes gestationis demonstrated by immunofluorescence basement membrane deposition of C3 and C5 in the absence of C1q, immunoglobulins, and light chains. A second patient with herpes gestationis had C3 deposition with no demonstrable immunoglobulins or light chains. A thermolabile humoral factor(s) capable of depositing C3 (without C1q or C4) on normal skin basement membrane was found in the sera of both patients with herpes gestationis. No anti-basement membrane antibodies could be demonstrated in the sera of these patients.The patients with systemic lupus erythematosus and bullous pemphigoid who manifested properdin deposition also showed skin basement membrane deposits of C1q, C4, C3, C5, and immunoglobulins. C3 proactivator (C3PA) was also found deposited along the skin basement membrane of three patients with systemic lupus erythematosus and all six bullous pemphigoid patients. This study provides suggestive evidence that activation of complement is occurring via the alternate pathway in herpes gestationis. In systemic lupus erythematosus and bullous pemphigoid, both the classical (antibody) mediated activation of complement as well as the alternate pathway may be operative.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4352464      PMCID: PMC302453          DOI: 10.1172/JCI107359

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  A DIALYSIS TECHNIQUE FOR PREPARING FLUORESCENT ANTIBODY.

Authors:  H F CLARK; C C SHEPARD
Journal:  Virology       Date:  1963-08       Impact factor: 3.616

2.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

3.  Secretory gamma-A in normal urine.

Authors:  J Bienenstock; T B Tomasi
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

4.  The biologic activities of guinea pig antibodies. I. Separation of gamma1 and gamma2 immunoglobulins and their participation in allergic reactions of the immediate type.

Authors:  B Oliveira; A G Osler; R P Siraganian; A L Sandberg
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

5.  Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study.

Authors:  J B van der Meer
Journal:  Br J Dermatol       Date:  1969-07       Impact factor: 9.302

6.  Decreased properdin activity in acute glomerulonephritis.

Authors:  H Gewurz; R J Pickering; G Naff; R Snyderman; S E Mergenhagen; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

7.  Herpes gestationis influenced by an oral contraceptive.

Authors:  J K Morgan
Journal:  Br J Dermatol       Date:  1968-07       Impact factor: 9.302

8.  Herpes gestationis. A new assessment of incidence, diagnosis, and fetal prognosis.

Authors:  R C Kolodny
Journal:  Am J Obstet Gynecol       Date:  1969-05-01       Impact factor: 8.661

9.  Homonal factors in herpes gestationis.

Authors:  F W Lynch; R J Albrecht
Journal:  Arch Dermatol       Date:  1966-04

10.  The human secretory immunoglobulin system: immunohistoligical localization of gamma A, secretory "piece," and lactoferrin in normal human tissues.

Authors:  D R Tourville; R H Adler; J Bienenstock; T B Tomasi
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  32 in total

1.  Immunologic phenomena in herpes gestationis.

Authors:  S Jablonska; T P Chorzelski; E H Beutner; E Maciejowska; G Rzesa
Journal:  Arch Dermatol Forsch       Date:  1975-07-18

Review 2.  Complement and cutaneous autoimmune blistering diseases.

Authors:  Elizabeth Lessey; Ning Li; Luis Diaz; Zhi Liu
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.

Authors:  L Borrego; B Maynard; E A Peterson; T George; L Iglesias; M S Peters; W Newman; G J Gleich; K M Leiferman
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

4.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

5.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

6.  Immunoglobulin and complement deposition in skin of rheumatoid arthritis and systemic lupus erythematosus patients.

Authors:  A L Schroeter; D L Conn; R E Jordon
Journal:  Ann Rheum Dis       Date:  1976-08       Impact factor: 19.103

7.  The immunopathology of herpes gestationis. Immunofluorescence studies and characterization of "HG factor".

Authors:  R E Jordon; K G Heine; G Tappeiner; L L Bushkell; T T Provost
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

8.  Complement in pemphigus vulgaris and other bullous dermatoses.

Authors:  E Sbano; A Auteri; M Fimiani; L Volpi
Journal:  Arch Dermatol Res       Date:  1975-12-10       Impact factor: 3.017

9.  Glomerulonephritis with mesangial deposits of IgA unassociated with systemic disease.

Authors:  A Katz; B J Underdown; J O Minta; I H Lepow
Journal:  Can Med Assoc J       Date:  1976-02-07       Impact factor: 8.262

10.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.

Authors:  Z Liu; L A Diaz; J L Troy; A F Taylor; D J Emery; J A Fairley; G J Giudice
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.